Lipocine Inc.
LPCN 1154
postpartum depression
Resolved
97days ago
Phase 3 readout · Apr 1, 2026
What's at stake
Phase 3 trial results for LPCN 1154 in postpartum depression are due Apr 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“We look forward to reporting topline safety and efficacy results early in the second quarter of 2026.”